A 72-year old female with multiple supra- and infratentorial dural masses.
作者信息
Kirschenbaum Daniel, Woernle Christoph, Haralambieva Eugenia, Marques Maggio Ewerton, Bernays René, Camenisch Ulrike, Rushing Elisabeth J
机构信息
Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland.
Neurosurgical Clinic Hirslanden, Zurich, Switzerland.
出版信息
Brain Pathol. 2018 Nov;28(6):1023-1024. doi: 10.1111/bpa.12666.
Abstract
摘要
相似文献
1
A 72-year old female with multiple supra- and infratentorial dural masses.一名72岁女性，患有多个幕上和幕下硬脑膜肿块。
Brain Pathol. 2018 Nov;28(6):1023-1024. doi: 10.1111/bpa.12666.
2
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).针对54例 Erdheim-Chester病患者的靶向治疗，包括中断治疗后的随访（LOVE研究）。
Blood. 2017 Sep 14;130(11):1377-1380. doi: 10.1182/blood-2017-03-771873. Epub 2017 Jun 30.
3
Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers.Erdheim-Chester病中BRAF抑制剂治疗所致急性胰腺炎：来自两家三级转诊中心的报告
Pancreas. 2021 Jan 1;50(1):e6-e8. doi: 10.1097/MPA.0000000000001704.
4
43-Year-Old Man With Polyuria and Bone Pain.
Mayo Clin Proc. 2020 Feb;95(2):e13-e18. doi: 10.1016/j.mayocp.2019.07.022.
5
Hypoalphalipoproteinemia and BRAF Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.低α脂蛋白血症和 BRAF 突变是 Erdheim-Chester 病主动脉浸润的主要预测因子。
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1913-1925. doi: 10.1161/ATVBAHA.118.310803.
6
Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.MEK抑制剂考比替尼治疗野生型BRAF Erdheim-Chester病的疗效。
Br J Haematol. 2018 Jan;180(1):150-153. doi: 10.1111/bjh.14284. Epub 2016 Oct 6.
7
Long-term follow-up of mTOR inhibition for Erdheim-Chester disease.mTOR 抑制剂治疗 Erdheim-Chester 病的长期随访
Blood. 2020 May 28;135(22):1994-1997. doi: 10.1182/blood.2019004478.
8
Vemurafenib as first-line therapy in -V600E-mutant Erdheim-Chester disease with CNS involvement.维莫非尼作为伴有中枢神经系统受累的-V600E突变型 Erdheim-Chester 病的一线治疗药物。
BMJ Case Rep. 2019 Nov 19;12(11):e228280. doi: 10.1136/bcr-2018-228280.
9
An effective treatment in Erdheim Chester disease: vemurafenib: a case report.厄德海姆-切斯特病的有效治疗：威罗非尼：一例报告。
J Med Case Rep. 2023 Oct 12;17(1):426. doi: 10.1186/s13256-023-04153-z.
10
[Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].[厄尔德海姆-切斯特病——一种具有不寻常肾脏受累的组织细胞多系统疾病]
Internist (Berl). 2020 Sep;61(9):969-979. doi: 10.1007/s00108-020-00849-2.
本文引用的文献
1
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.巨噬细胞-树突状细胞谱系组织细胞增多症和肿瘤的修订分类
Blood. 2016 Jun 2;127(22):2672-81. doi: 10.1182/blood-2016-01-690636. Epub 2016 Mar 10.
2
Erdheim-Chester disease.厄德海姆-切斯特病。
Eur J Intern Med. 2015 May;26(4):223-9. doi: 10.1016/j.ejim.2015.03.004. Epub 2015 Apr 10.
3
Erdheim-Chester disease: a systematic review.Erdheim-切斯特病：一项系统综述。
Crit Rev Oncol Hematol. 2015 Jul;95(1):1-11. doi: 10.1016/j.critrevonc.2015.02.004. Epub 2015 Feb 17.
4
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.携带 BRAF V600E 突变的多系统和难治性 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症中维莫非尼的显著疗效。
Blood. 2013 Feb 28;121(9):1495-500. doi: 10.1182/blood-2012-07-446286. Epub 2012 Dec 20.
Zotero 插件